JSB Market Research: PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - PowerPoint PPT Presentation

About This Presentation
Title:

JSB Market Research: PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022

Description:

During the forecast period from 2012-2022, the growth of the ulcerative colitis market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. See More: – PowerPoint PPT presentation

Number of Views:55

less

Transcript and Presenter's Notes

Title: JSB Market Research: PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022


1
JSB Market Research PharmaPoint Ulcerative
Colitis - Global Drug Forecast and Market
Analysis to 2022
To buy this Report Visit http//www.jsbmarketrese
arch.com
  • i

2
Summary
During the forecast period from 2012-2022, the
growth of the ulcerative colitis market will be
driven largely by the entry of Johnson Johnsons
(JJs) Simponi and Takedas Entyvio, which will
lead to an increase in the overall number of
patients being treated with biologics in the US,
5EU, Japan, and Canada. Another key event
affecting the UC market is the anticipated launch
of biosimilars, given that the patent expiry of
the UC blockbusters, Remicade and Humira are set
to expire in the US in 2018 and 2016,
respectively.
  • i

3
Key Highlights
  • The UC market has predominantly been driven by
    two TNF blockers, namely JJs Remicade and
    AbbVies Humira. Although these TNF blockers have
    monopolized the UC market for almost a decade,
    the balance is about to be tipped, with Takedas
    Entyvio imminently entering the market in 2014
    and JJs Simponi launching in 2014 as well,
    stealing market share from Humira and Remicade.
  • Remicade and Humira will also be hit by their
    respective loss of patent protection in 2018
    (US), 2015 (EU) and 2016 (US), 2018 (EU). Europe
    has already approved a biosimilar to Remicade,
    Celltrions Remsima, which will be marketed by
    Hospira under the brand name Inflectra in the EU.
  • To know more about this report click here
  • http//www.jsbmarketresearch.com/healthcare-medica
    l/r-PharmaPoint-Ulcerative-Colitis-Global-Drug-For
    ecast-and-Market-Analysis-114234
  • i

4
Table of Contents
PharmaPoint Ulcerative Colitis - Global Drug
Forecast and Market Analysis to 2022
Etiology 26
Quality of Life 31
Pathophysiology 29
Symptoms 30
  • i

5
Related Market Research Report
  • Molecular Diagnostics Market by Application
    (Infectious Disease, Oncology, Genetics,
    Microbiology), Technology (PCR, INAAT, DNA
    Sequencing), End User (Hospital, Laboratories),
    Product (Instruments, Reagent, Service, Software)
    - Global Forecasts to 2018
  • Breast Imaging Technologies Market (Analog
    Mammography, Digital Mammography, Tomosynthesis,
    Positron Emission Mammography, PET/CT, MBI,
    Breast MRI, Ultrasound, Optical Imaging, Whole
    Breast Ultrasound, Breast Thermography) - Global
    Forecasts to 2019
  • Rectal Cancer - Pipeline Review, H2 2014
  • Arteriosclerosis - Pipeline Review, H2 2014
  • i

6
About JSB Market Research
  • Jsbmarketresearch.com is an online repository of
    an extensive collection of market research
    reports available online. This online portal
    contains high-quality reports with
    well-researched and high-quality content on a
    wide range of industries. These market research
    reports help us give a detailed insight into new
    opportunities in the industry, prevailing market
    trends, competitor analysis and future prospects.
  • JSBs reports are developed by the domain experts
    and publishers under a closely observed
    surveillance of industry specialists. Therefore,
    the researched data is well researched, well-
    organized and matching up to the best standards
    in the industry. Also JSBs database consists of
    detailed insights of the leading players in the
    global market, products and trends.
  • i

7
Contact Us
  • Support General Inquiries
  • Mail support_at_jsbmarketresearch.com
    91 - 998 729 5242
  • Billing Support
  • Mail billing_at_jsbmarketresearch.com
    91 22 412 366 50
  • Website- http//www.jsbmarketresearch.com
  • i
Write a Comment
User Comments (0)
About PowerShow.com